Jacksonville, Florida 32256

  • Dry Eye Disease


This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.

Study summary:

This is a phase 4, multicenter, open-label, single-arm, 12-week study of subjects with dry eye disease that is inadequately controlled by cyclosporine (CsA) 0.05% ophthalmic emulsion. Subject enrollment will be classified by evidence of dry eye disease (ie, signs, symptoms, or both signs and symptoms). Treatment will be one drop of CsA 0.09% ophthalmic solution (Cequa) in each eye twice daily (BID) for 12 weeks. The study hypothesis is that CsA 0.09% ophthalmic solution will show improved clinical benefit in subjects whose dry eye signs and/or symptoms are inadequately controlled while on CsA.


Inclusion Criteria: 1. Male or female subjects with a history of bilateral dry eye disease for a period of at least 3 months. 2. Aged of at least 18 years. 3. Subjects with total corneal fluorescein staining ≥6 or corneal fluorescein staining in an individual zone ≥2 as per National Eye Institute Grading Scale. 4. Subjects with modified symptom assessment in dry eye global symptom score, ≥40 using visual analogue scale. 5. Subjects with best-corrected visual acuity 20/200 or better in both eyes at the Screening/Baseline visit Exclusion Criteria: 1. Subjects who have used cyclosporin 0.05% ophthalmic emulsion in both eyes for less than 3 months prior to the Screening/Baseline visit. 2. Subjects with history of treatment failure with cyclosporin 0.05% ophthalmic emulsion. 3. Subjects who have active seasonal and/or perennial allergic conjunctivitis in either eye. 4. Subjects who had already Use initiated any systemic or topical ocular medication.



Primary Contact:

Head Clinical Development
Phone: +912266455645
Email: Clinical.Trials@sparcmail.com

Backup Contact:


Location Contact:

Jacksonville, Florida 32256
United States

Frank Bowden, MD
Phone: 904-861-3858
Email: fbowden3@hotmail.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.